A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma

Lili Mao,Jun Guo,Lingjun Zhu,Yu Jiang,Wangjun Yan,Jian Zhang,Ai-Min Hui,Yuchen Yang,Lei Diao,Yan Tan,Han Zhao,Yiqian Jiang,Zhuli Wu,Lu Si
DOI: https://doi.org/10.1016/j.ejca.2022.08.005
IF: 10.002
2022-01-01
European Journal of Cancer
Abstract:•There is currently no standard targeted therapy for advanced NRASmut melanoma.•FCN-159, a selective MEK1/2 inhibitor, was evaluated in a first-in-human study.•FCN-159 was well tolerated in Chinese patients with advanced NRASmut melanoma.•Preliminary signs of antitumour activity were observed at FCN-159 doses ≥6 mg QD.•The findings support further study of FCN-159 in patients with NRASmut melanoma.
What problem does this paper attempt to address?